Effect of Spesolimab on Achieving Sustained Disease Remission in Patients with Generalized Pustular Psoriasis: Results from the Effisayil 2 Study

Main Article Content

Kenneth Gordon
Mark Lebwohl
Jonathan Barker
Tsen-Fang Tsai
Joseph Merola
Curdin Conrad
Min Zhang
Na Hu
Patrick Hofmann
Christian Thoma
Kilian Eyerich


Effisayil 2, spesolimab, GPP, sustained disease remission


 Introduction: Generalized pustular psoriasis (GPP) is a chronic, rare disease characterized by flares of widespread skin pustulation. Intravenous (IV) spesolimab, an anti-interleukin-36 receptor monoclonal antibody, is approved for GPP flare treatment; however, the optimal dosing and long-term efficacy of subcutaneous (SC) spesolimab treatment in patients with GPP has not yet been reported. We report the effect of SC spesolimab on achieving sustained disease remission in Effisayil 2 (NCT04399837), a 48-week trial that evaluated the efficacy and safety of SC spesolimab in preventing GPP flares.

 Methods: Patients with a history of GPP were randomized (1:1:1:1) to receive placebo (n=31), low- (n=31, 300 mg loading dose [LD]; 150 mg every 12 weeks [q12w]), medium- (n=31, 600 mg LD; 300 mg q12w) or high-dose (n=30, 600 mg LD; 300 mg every 4 weeks [q4w]) SC spesolimab over 48 weeks. Sustained remission was defined as GPP Physician Global Assessment (GPPGA) total score of 0 or 1 at all visits up to Week 48, or GPPGA total score of 0 or 1 and all GPPGA subscores ≤2 at all visits up to Week 48. Sustained pustular clearance was defined as GPPGA pustulation subscore of 0 at all visits from Week 4 to Week 48. Any use of IV spesolimab or another standard of care for GPP worsening was considered a failure of remission. Missing data were imputed by a sequential logistic regression multiple imputation method. Adjusted risk differences (RD) were calculated by the Mantel−Haenszel type-weighted average of differences.

 Results: 31 patients received placebo, and 30 patients received high-dose spesolimab. Compared to placebo, more patients had sustained remission in the high-dose arm using both GPPGA total score 0 or 1 (63.3% vs 29.0%; RD [95% CI] 0.35 [0.10–0.59]), and GPPGA total score 0 or 1 and all GPPGA subscores ≤2 (60.4% vs 29.0%; RD [95% CI] 0.32 [0.07–0.56]). Compared to placebo, more patients in the high-dose arm had sustained pustular clearance over 48 weeks (63.6% vs 25.8%; RD [95% CI] 0.38 [0.14–0.62]).

Conclusion: Overall, high-dose SC spesolimab q4w is effective for the long-term management of GPP skin symptoms.


1. Navarini AA, et al. J Eur Acad Dermatol Venereol 2017;31:1792–1799.

2. Bachelez H, et al. Expert Rev Clin Immunol 2022;18:1033–1047.

3. Puig L, et al. J Eur Acad Dermatol Venereol 2023;37:737–752.

4. Bachelez H, et al. N Engl J Med 2021;385:2431–2440.

5. SPEVIGO® prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761244s000lbl.pdf (accessed 29 Sept 2023).

6. Morita A, et al. Derm Ther 2023;13:347–359.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>